Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6550865 | 0.82 | GPR3 (0.41) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL70001 | 0.64 | GPR3 (0.44) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL25434268 | 0.62 | — | — | |
| SCHEMBL13185884 | 0.61 | GPR3 (0.41) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL8458737 | 0.61 | GPR3 (0.41) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL27742167 | 0.59 | CASP3 (0.48) | HDAC4HDAC8HDAC6 | |
| SCHEMBL68634 | 0.58 | GPR3 (0.38) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL19417387 | 0.58 | NPC1 (0.38) | — | |
| SCHEMBL221399 | 0.57 | GPR3 (0.46) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL3837050 | 0.56 | GPR3 (0.37) | HDAC3HDAC4HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | claimed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | claimed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | claimed |
| US-8324173-B2 | Peptides useful as dual caspase-2/-6 inhibitors and their biological applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-04 | — | — | US | disclosed |
| US-8173600-B2 | Caspase-2 inhibitors and their biological applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20120021990-A1 | PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | CHAUVIER DAVID (FR) | 2012-01-26 | — | — | US | disclosed |
| CN-101052651-B | Caspase-2 inhibitors and their biological applications | THERAPTOSIS S A | 2011-05-25 | — | — | CN | disclosed |
| WO-2009083930-A1 | CASPASE-8 INHIBITORS AND USES THEREOF | THERAPTOSIS (FR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083929-A1 | CASPASE-1 INHIBITORS AND USES THEREOF | THERAPTOSIS (FR) | 2009-07-09 | — | — | WO | disclosed |
| US-20090042805-A1 | Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-02-12 | — | — | US | disclosed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| CN-101052651-A | Caspase-2 inhibitors and their biological applications | THERAPTOSIS S A (FR) | 2007-10-10 | — | — | CN | disclosed |
| EP-1817328-A2 | NEW PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-08-15 | — | — | EP | disclosed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006056487-A2 | PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042805-A1 | Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications | CASP6, CASP2, CASP4 | HDAC3 1605/4885HDAC4 756/4885HDAC7 899/4885 |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | CASP1, CASP2, CASP9 | HDAC3 1256/4885HDAC4 1143/4885HDAC7 1272/4885 |
| US-20120021990-A1 | PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | CASP6, CASP2, CASP1 | HDAC3 1989/4885HDAC4 2050/4885HDAC7 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.